Amneal Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Amneal Pharmaceuticals's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8% to $2,393,607,000. The net income raised on -$83,993,000 and profit margin reached -4%. Total operating expenses were $616,191,000.
Profit Margin
| 2014 | 785.62M | 176.92M | 22.52% |
|---|---|---|---|
| 2015 | 866.28M | 169.45M | 19.56% |
| 2016 | 1.01B | 207.37M | 20.37% |
| 2017 | 1.03B | 167.64M | 16.22% |
| 2018 | 1.66B | -169.72M | -10.21% |
| 2019 | 1.62B | -603.57M | -37.11% |
| 2020 | 1.99B | 68.57M | 3.44% |
| 2021 | 2.09B | 20.17M | 0.96% |
| 2022 | 2.21B | -254.78M | -11.52% |
| 2023 | 2.39B | -83.99M | -3.51% |
AMRX Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 2.39B | 2.21B | 2.09B | 1.99B | 1.62B | 1.66B | 1.03B | 1.01B | 866.28M | 785.62M |
Cost of revenue | 1.57B | 1.42B | 1.32B | 1.36B | 1.27B | 946.58M | 507.47M | 420.77M | 367.05M | 335.98M |
Gross profit | 820.56M | 784.70M | 768.97M | 628.39M | 352.99M | 716.40M | 526.17M | 597.45M | 499.22M | 449.63M |
Operating exp. | ||||||||||
Research and development | 167.77M | 200.04M | 209.56M | 190.58M | 202.28M | 210.45M | 191.93M | 204.74M | 136.87M | 106.73M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 616.19M | 595.78M | 575.06M | 517.31M | 491.88M | 440.88M | 300.98M | 323.50M | 277.80M | 239.63M |
Operating income | 204.37M | 206.46M | 209.23M | 91.15M | -137.42M | -19.67M | 245.10M | 284.88M | 227.23M | 222.94M |
Other income (expenses), net | -244.64M | -454.59M | -177.87M | -126.93M | -82.81M | -334.66M | -73.78M | -3.84M | -60.57M | -39.24M |
Income before tax | -40.27M | -248.12M | 31.36M | -35.78M | -220.24M | -202.72M | 171.32M | 214.82M | 175.58M | 179.33M |
Income tax expense | 8.45M | 6.66M | 11.19M | -104.35M | 383.33M | -1.41M | 1.99M | 5.39M | 4.95M | 1.51M |
Net income | -83.99M | -254.78M | 20.17M | 68.57M | -603.57M | -169.72M | 167.64M | 207.37M | 169.45M | 176.92M |
Earnings per share | ||||||||||
Basic EPS | -0.48 | -1.69 | 0.14 | 0.47 | -4.57 | -1.33 | 1.46 | 1.81 | 0.9 | 0 |
Diluted EPS | -0.48 | -1.69 | 0.13 | 0.46 | -4.57 | -1.33 | 1.46 | 1.81 | 0.9 | 0 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |